-
公开(公告)号：US20230381385A1
公开(公告)日：2023-11-30
申请号：US18201396
申请日：2023-05-24
Inventor： Alhaji Cherif , Paulo Paneque Galuzio , Peter Kotanko , Juergen Klewinghaus , David Thompson
IPC: A61M1/16
CPC classification number: A61M1/1613 , A61M2230/202
Abstract: The described technology may include processes to model acid-base homeostasis in normal patients and under acid-base disorder conditions. In one embodiment, a method may include an acid-base homeostasis analysis process. The method may include, via a processor of a computing device, providing an acid-base model configured to model acid-base homeostasis of a patient, the acid-base model comprising a patient model, a dialyzer model, and an extracorporeal CO2 removal device (ECCO2RD), and determining predicted patient information using the acid-base model. Other embodiments are described.
-
公开(公告)号：US11640846B2
公开(公告)日：2023-05-02
申请号：US17162030
申请日：2021-01-29
Applicant: Fresenius Medical Care Holdings, Inc.
Inventor： Xia Tao , Vaibhav Maheshwari , Peter Kotanko , Stephan Thijssen , Nadja Grobe
Abstract: Systems, methods, and/or apparatuses may be operative to perform a dialysis process that includes a displacer infusion process. In one embodiment, a method for determining a displacer compound may include constructing a plurality of target protein quantitative structure-activity relationship (QSAR) models, one for each of the plurality of binding sites, analyzing a set of candidate compounds using the plurality of QSAR models to determine a set of at least one potential compound with an affinity for binding to each of the plurality of binding sites, and selecting at least one displacer compound from the set of at least one potential compound. Other embodiments are described.
-
公开(公告)号：US20230001064A1
公开(公告)日：2023-01-05
申请号：US17943377
申请日：2022-09-13
Applicant: Fresenius Medical Care Holdings, Inc.
Inventor： Vaibhav Maheshwari , Peter Kotanko
IPC: A61M1/34 , G06F15/16 , A61M5/142 , A61M1/16 , G06F9/30 , G06F15/167 , G06F15/163 , G06F17/11 , A61M1/28
Abstract: Systems, methods, and/or apparatuses may be operative to perform a dialysis process that includes a displacer infusion process. The dialysis machine may include at least one processor and a memory coupled to the at least one processor, the memory comprising instructions that, when executed by the processor, may cause the at least one processor to access dialysis information for a dialysis process performed by a dialysis machine, the dialysis information indicating a target substance to be displaced from a binding compound by a displacer, and determine an infusion profile for infusing the displacer into a patient during a displacer infusion process of the dialysis process, the infusion profile determined based on the dialysis information and an infusion constraint. Other embodiments are described.
-
公开(公告)号：US20220399128A1
公开(公告)日：2022-12-15
申请号：US17829697
申请日：2022-06-01
Applicant: Fresenius Medical Care Holdings, Inc.
Inventor： Alhaji Cherif , Peter Kotanko , Paulo Galuzio
Abstract: The described technology may include processes to model renal pathophysiology in patients and/or patient populations. In one embodiment, a method may include a CKD/ESRD condition analysis, such as a vascular calcification analysis. The method may include, via a processor of a computing device: determining a vascular calcification model configured to model vascular calcification of a virtual patient to determine a causal relationship between at least one patient characteristic and a vascular calcification indicator, and generating a causal relationship structure configured to visualize a causal relationship between the at least one patient characteristic and the vascular calcification indicator. Other embodiments are described.
-
公开(公告)号：US11450405B2
公开(公告)日：2022-09-20
申请号：US16655873
申请日：2019-10-17
Applicant: Fresenius Medical Care Holdings, Inc.
Inventor： Gudrun Schappacher-Tilp , Peter Kotanko , Doris Helen Fuertinger
IPC: G16B5/00 , G06F30/20 , G06F111/10 , G06F17/16
Abstract: The described technology may include processes to model parathyroid gland (PTG) functionality and/or calcimimetic administration to patients with a health abnormality that affects PTG function. In one embodiment, a method may include providing a PTG functionality model configured to simulate functionality of a PTG of a patient with a health abnormality affecting PTG function, the model may receive a parameters configured to regulate activity of calcium-sensing receptors (CaSR), the parameters may include a calcium concentration, a vitamin D concentration, and a phosphorous concentration, simulate CaSR expression and vitamin D receptor (VDR) expression via a positive feedback loop between the CaSR expression and the VDR expression, and suppression of the CaSR expression and the VDR expression by P, initiate at least one PTG adaptation based on the parameters, and determine a model output comprising a parathyroid hormone (PTH) concentration at one or more time intervals. Other embodiments are described.
-
Patent Agency Ranking
公开(公告)号：US20220240806A1
公开(公告)日：2022-08-04
申请号：US17720521
申请日：2022-04-14
Applicant: Fresenius Medical Care Holdings, Inc.
Inventor： Fansan Zhu , Peter Kotanko
IPC: A61B5/0537 , A61B5/0531 , A61B5/055 , A61B5/145 , A61B5/1477 , A61B5/00
Abstract: A technique for determining skin sodium content using bioimpedance spectroscopy includes applying a current at a predetermined frequency to skin of a subject, measuring a voltage across the skin of the subject produced by the current, determining a resistance across the skin of the subject at the predetermined frequency using the measured voltage, and determining skin sodium content using the measured voltage.
-
公开(公告)号：US20220193320A1
公开(公告)日：2022-06-23
申请号：US17132710
申请日：2020-12-23
Inventor： Sabrina Rogg , Peter Kotanko
Abstract: A method for detecting occult hemorrhages is provided. The method comprises: obtaining, by a medical system comprising a blood monitoring system, a first hematocrit concentration prior to infusing a saline solution into a bloodstream of the patient; infusing, by the medical system, the saline solution into the bloodstream of the patient; obtaining, by the medical system, a second hematocrit concentration after infusing the saline solution into the bloodstream; determining, by the medical system, a first absolute blood volume based on the first hematocrit concentration and the second hematocrit concentration; generating, by the medical system, a notification indicating a potential occult hemorrhage based on the first absolute blood volume and a pre-defined absolute blood volume threshold; and providing, by the medical system, the notification indicating the potential occult hemorrhage.
-
8.发明申请公开(公告)号：US20210308354A1
公开(公告)日：2021-10-07
申请号：US16841529
申请日：2020-04-06
Applicant: Fresenius Medical Care Holdings, Inc.
Inventor： Peter Kotanko , Stephan Thijssen , Priscila Preciado , Israel D. Campos , Xia Tao
Abstract: A hemodialysis system includes: a hemodialysis machine configured to provide hemodialysis treatment to a patient, wherein the hemodialysis treatment includes circulating extracorporeal blood of the patient through an extracorporeal blood circuit; a first oxygen saturation sensor device configured to measure oxygen saturation corresponding to the extracorporeal blood of the patient in the extracorporeal blood circuit; a second oxygen saturation sensor device configured to measure oxygen saturation corresponding to blood flowing within the patient; and at least one controller configured to determine one or more oxygen saturation phase shift (OSPS) values or one or more transcutaneous travel time values corresponding to the patient based on oxygen saturation measurements from the first oxygen saturation sensor device and the second oxygen saturation sensor device.
-
公开(公告)号：US20210241848A1
公开(公告)日：2021-08-05
申请号：US17162030
申请日：2021-01-29
Applicant: Fresenius Medical Care Holdings, Inc.
Inventor： Xia Tao , Vaibhav Maheshwari , Peter Kotanko , Stephan Thijssen , Nadja Grobe
Abstract: Systems, methods, and/or apparatuses may be operative to perform a dialysis process that includes a displacer infusion process. In one embodiment, a method for determining a displacer compound may include constructing a plurality of target protein quantitative structure-activity relationship (QSAR) models, one for each of the plurality of binding sites, analyzing a set of candidate compounds using the plurality of QSAR models to determine a set of at least one potential compound with an affinity for binding to each of the plurality of binding sites, and selecting at least one displacer compound from the set of at least one potential compound. Other embodiments are described.
-
公开(公告)号：US20210215666A1
公开(公告)日：2021-07-15
申请号：US16739366
申请日：2020-01-10
Applicant: FRESENIUS MEDICAL CARE HOLDINGS, INC.
Inventor： Peter Kotanko , Xia Tao , Mia G. Garbaccio , Stephan Thijssen , Nadja Grobe , Leticia M. Tapia Silva
IPC: G01N33/487 , A61M1/28 , C12Q1/06 , G01N21/59
Abstract: An apparatus used in analyzing spent dialysate includes at least a first surface configured to accommodate a dialysate drain bag in a first predetermined position, and at least a second surface configured to accommodate a dialysate analysis device in a second predetermined position, such that when the dialysate drain bag is in the first predetermined position and the dialysate analysis device is in the second predetermined position, a light sensor of the dialysate analysis device is positioned to sense light passing through the dialysate drain bag.
-
-
-
-
-
-
-
-
-
Search Results
101
records
(took 0.051 seconds)
